인간 인슐린 시장 : 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카) - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research provides a comprehensive analysis of the global Human Insulin Market, offering insights into market trends, growth drivers, challenges, and emerging opportunities. This study delves into the landscape of the human insulin sector, providing vital statistics and projections delineating the market trajectory from 2024 to 2031.

Key Insights:

• Human Insulin Market Size (2024): USD 52.03 Billion
• Projected Market Value (2031): USD 89.02 Billion
• Global Market Growth Rate (CAGR 2024 to 2031): 7.97%

Human Insulin Market - Report Scope:

The Human Insulin Market encompasses a wide array of insulin products utilized in the management of diabetes mellitus. These products include rapid-acting, short-acting, intermediate-acting, and long-acting insulins, catering to the diverse needs of diabetic patients. The market serves hospitals, clinics, retail pharmacies, and online pharmacies, providing essential insulin therapies to improve glycemic control and enhance patient quality of life.

Market Growth Drivers:

The global Human Insulin Market experiences significant growth driven by several key factors. The rising prevalence of diabetes worldwide, coupled with increasing awareness about the importance of insulin therapy in diabetes management, propels demand for human insulin products. Technological advancements in insulin delivery devices, such as insulin pens, pumps, and inhalers, enhance treatment adherence and patient convenience, thereby driving market expansion. Moreover, initiatives aimed at improving access to insulin in low- and middle-income countries, along with strategic partnerships between pharmaceutical companies and healthcare organizations, contribute to market growth.

Market Restraints:

Despite robust growth prospects, the Human Insulin Market faces challenges related to pricing pressures, regulatory hurdles, and competition from biosimilar insulins. Pricing dynamics in the insulin market, characterized by complex rebate structures and formulary negotiations, impact product affordability and market access for patients. Additionally, regulatory requirements for insulin manufacturing and approval processes entail significant investments and time-to-market delays, hindering new product introductions. Furthermore, the emergence of biosimilar insulins poses a competitive threat to branded human insulin manufacturers, leading to pricing pressures and market share erosion.

Market Opportunities:

The Human Insulin Market presents promising opportunities driven by advancements in insulin analogs, personalized medicine approaches, and digital health solutions. Innovations in insulin formulations, such as ultra-rapid-acting and ultra-long-acting insulins, offer improved glycemic control and reduced risk of hypoglycemia, addressing unmet needs in diabetes care. Moreover, integration of digital technologies, including continuous glucose monitoring systems and insulin dose calculators, enables personalized insulin therapy management and remote patient monitoring, enhancing treatment outcomes. Furthermore, collaborations between pharmaceutical companies, diabetes advocacy groups, and governmental organizations facilitate access to affordable insulin and diabetes education programs, fostering market growth and patient empowerment.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Human Insulin Market globally?
• How are technological advancements and patient-centric approaches shaping the evolution of insulin therapies and delivery devices?
• What are the key challenges and opportunities facing market participants in the insulin market segment?
• Which geographic regions and healthcare settings offer the highest growth potential for human insulin products?
• What strategies are leading companies employing to enhance product innovation, market access, and patient outcomes in the competitive landscape of diabetes care?

Competitive Intelligence and Business Strategy:

Leading players in the global Human Insulin Market, including multinational pharmaceutical companies, biotechnology firms, and diabetes care providers, focus on innovation, market expansion, and patient-centricity to maintain a competitive edge. These companies invest in research and development to develop novel insulin formulations, delivery systems, and digital health solutions aligned with patient preferences and clinical guidelines. Moreover, strategic collaborations with healthcare providers, payers, and patient advocacy organizations enable insulin manufacturers to drive market access, reimbursement, and patient support programs. Additionally, emphasis on real-world evidence generation, health economics outcomes research, and patient-reported outcomes fosters continuous improvement and value-based innovation in the dynamic landscape of diabetes care.

Key Companies Profiled:

• Novo Nordisk A/S.
• Eli Lilly and Company.
• Sanofi.
• Biocon.
• Tonghua Dongbao Pharmaceutical Co., Ltd.
• Adocia, Merck & Co., Inc.
• Pfizer, Inc.
• Wockhardt.
• Julphar.
• Bristol-Myers Squibb Company.
• GlaxoSmithKline Plc.
• Oramed Pharmaceuticals, Inc.

Human Insulin Market Segmentation

Human Insulin Market by Type

• Modern Human Insulin

oFast-acting

oLong-acting

oPremix

• Traditional Human Insulin

oLong-acting

oShort-acting

oFast-acting

oPremix

Human Insulin Market by Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Human Insulin Market by Type of Diabetes

• Diabetes Type 1
• Diabetes Type 2

Human Insulin by Region

• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East & Africa (MEA)

Table of Contents

1. Preface

• 1.1. Report Description
• 1.2. Research Methodology
• 1.3. Assumptions

2. Market Synopsis

3. Porter's Five Forces Analysis

• 3.1. Bargaining Power of Suppliers
• 3.2. Bargaining Power of Buyers
• 3.3. Threat of New Entrants
• 3.4. Threat of Substitutes
• 3.5. Intensity of Rivalry

4. Industry Overview

• 4.1. Market Definition
• 4.2. Market Drivers
  • 4.2.1. Growing prevalence of diabetes
  • 4.2.2. Technological advancements in human insulin delivery devices
  • 4.2.3. Increasing awareness among people towards diabetes care
• 4.3. Impact Analysis of Market Drivers
• 4.4. Market Restraints
  • 4.4.1. Uneven pricing and limited access to human insulin in emerging countries
  • 4.4.2. Strict regulatory requirements for drug approval
• 4.5. Impact Analysis of Market Restraints
• 4.6. Market Trends
  • 4.6.1. Increasing usage of insulin pens for administration of human insulin

5. Global Market Size and Forecast

6. Market Size and Forecast by Type

• 6.1. Traditional Human Insulin
• 6.2. Modern Human Insulin

7. Market Size and Forecast of Traditional Human Insulin by Type

• 7.1. Short-acting Human Insulin
• 7.2. Intermediate-acting Human Insulin
• 7.3. Premixed Human Insulin

8. Market Size and Forecast of Modern Human Insulin by Type

• 8.1. Rapid-acting Human Insulin
• 8.2. Long-acting Human Insulin
• 8.3. Premixed Human Insulin

9. Market Size and Forecast by Disease

• 9.1. Type 1 Diabetes
• 9.2. Type 2 Diabetes

10. Market Size and Forecast by Brand

• 10.1. Traditional Human Insulin Brand
• 10.2. Modern Human Insulin Brand

11. Market Size and Forecast by Geography

• 11.1. North America
  • 11.1.1. Scenario in the U.S.
  • 11.1.2. Scenario in Canada
• 11.2. Europe
  • 11.2.1. Scenario in Germany
  • 11.2.2. Scenario in France
  • 11.2.3. Scenario in the U.K.
• 11.3. Asia Pacific
  • 11.3.1. Scenario in Japan
  • 11.3.2. Scenario in China
  • 11.3.3. Scenario in India

12. Pipeline Drugs for Diabetes Treatment

• 12.1. Drugs Under Development for Diabetes Treatment

13. Competitive Scenario

• 13.1. Competitive Benchmarking

14. Company Profiles

• 14.1. Novo Nordisk A/S
  • 14.1.1. Company overview
  • 14.1.2. Products and services
  • 14.1.3. Financial performance
  • 14.1.4. Key developments
• 14.2. Eli Lilly and Company
  • 14.2.1. Company overview
  • 14.2.2. Products and services
  • 14.2.3. Financial performance
  • 14.2.4. Key developments
• 14.3. Sanofi
  • 14.3.1. Company overview
  • 14.3.2. Products and services
  • 14.3.3. Financial performance
  • 14.3.4. Key developments
• 14.4. Biocon
  • 14.4.1. Company overview
  • 14.4.2. Products and services
  • 14.4.3. Financial performance
  • 14.4.4. Key developments
• 14.5. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 14.5.1. Company overview
  • 14.5.2. Products and services
  • 14.5.3. Financial performance
  • 14.5.4. Key developments
• 14.6. ADOCIA
  • 14.6.1. Company overview
  • 14.6.2. Products and services
  • 14.6.3. Financial performance
  • 14.6.4. Key developments
• 14.7. Wockhardt
  • 14.7.1. Company overview
  • 14.7.2. Products and services
  • 14.7.3. Financial performance
  • 14.7.4. Key developments
• 14.8. Julphar
  • 14.8.1. Company overview
  • 14.8.2. Products and services
  • 14.8.3. Financial performance
  • 14.8.4. Key developments
• 14.9. Merck & Co., Inc.
  • 14.9.1. Company overview
  • 14.9.2. Products and services
  • 14.9.3. Financial performance
  • 14.9.4. Key developments
• 14.10. Pfizer, Inc.
  • 14.10.1. Company overview
  • 14.10.2. Products and services
  • 14.10.3. Financial performance
  • 14.10.4. Key developments
• 14.11. Bristol-Myers Squibb Company
  • 14.11.1. Company overview
  • 14.11.2. Products and services
  • 14.11.3. Financial performance
  • 14.11.4. Key developments
• 14.12. GlaxoSmithKline Plc
  • 14.12.1. Company overview
  • 14.12.2. Products and services
  • 14.12.3. Financial performance
  • 14.12.4. Key developments
• 14.13. Oramed Pharmaceuticals, Inc.
  • 14.13.1. Company overview
  • 14.13.2. Products and services
  • 14.13.3. Financial performance
  • 14.13.4. Key developments